Richmond Pharmacology's Volunteer Database Exceeds 100,000 Volunteer Registration Records

Posted:
14
April 2010

14th April 2010

Richmond Pharmacology�s Volunteer Database Exceeds100,000 Volunteer Registration Records

Richmond Pharmacology registered its 100,000th volunteer on Tuesday the 16th of February 2010, � making our Volunteer Database the UK�s single largest database for clinical trial participation.

  • VORSPRUNG

RPL recently completed the recruitment for a POC/PD trial requiring 70 patients suffering from Relapsing Remitting Multiple Sclerosis; this was done in just 6 months, which to our knowledge is the fastest ever recruitment project in this patient population. This has allowed the sponsor significantly faster decision making.RPL also recently completed the recruitment for Europe�s first paediatric clinical trial in healthy adolescent girls. Recruitment commenced within days from Ethics Committee approval and was completed in less than two weeks.RPL is currently conducting a large scale dose escalation study requiring the inclusion of 72 Japanese for a specialist anesthetic study where each participant is to be anesthetized. Our unique capability to recruit large panels of first generation Japanese male and female volunteers has made us the leading provider of these studies in Europe.

  • DURCH

From the inception of the company, the recruitment process was given an equal footing within the company through the installation of a dedicated professional recruitment team, which has been the largest and most effective of any early phase CRO in the UK along with a strong branded marketing presence within the general population.This has enabled RPL to recruit a multitude of volunteer panels including special panels such as young healthy, elderly healthy, Japanese and patients from primary and secondary care quickly and efficiently. Multiple feedback loops within our custom built database system has always allowed us to steer towards meeting out recruitment targets in time even when timelines are moved at short notice; capabilities for which RPL is well recognized within the industry in addition to our renowned First Time in Human and TQT/cardiac safety capabilities.

  • INNOVATION

Staying ahead of the competition is essential to our continuing success as a contract research organisation. This combined with a proprietary volunteer database in excess of 100,000 strong, means that we can guarantee the delivery of a variety of healthy volunteer and patient panels on time and within budget.

Book your site visit today;You can be confident that Richmond Pharmacology will always rise to the challenge!

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more